Abstract：
BACKGROUND: The role of non-HLA antibody is gaining special attention in solid-organ transplantation and in highly sensitized (HS) patients because of its potential involvement in graft loss (GL) and/or antibody-mediated rejection (ABMR). The identification of non-HLA antibodies while listed may provide deeper information about the increased immunologic risk prior to transplant. We aimed to identify non-HLA antibodies pretransplant that could involve GL in HS patients.
METHODS: Nineteen pretransplant samples from HS patients who underwent transplant at the Marqués de Valdecilla University Hospital were studied for both HLA antibodies and a panel of 39 non-HLA antigens analyzed based on Luminex platform.
RESULTS: Eleven patient (57.9%) maintained the graft (KT group), whereas 8 (42.1%) had a GL within a median of 30 days. The median fluorescent intensity (MFI) of the 39 non-HLA antigens were compared within the groups, obtaining a statistically significant differences in protein tyrosine phosphatase receptor type N (P < .04) with a MFI mean of 1408 vs 4931 for KT and GL groups, respectively. However, no significant differences were observed in non-HLA MFI between ABMR and non-ABMR KT recipients.
CONCLUSIONS: The presence of non-HLA antibodies in HS is high. The levels of anti-protein tyrosine phosphatase receptor type N before transplant could indicate a potential risk of GL, although longitudinal studies with large number of cases are needed to define anti-non-HLA profiles of risk of ABMR.
METHODS: Nineteen pretransplant samples from HS patients who underwent transplant at the Marqués de Valdecilla University Hospital were studied for both HLA antibodies and a panel of 39 non-HLA antigens analyzed based on Luminex platform.
RESULTS: Eleven patient (57.9%) maintained the graft (KT group), whereas 8 (42.1%) had a GL within a median of 30 days. The median fluorescent intensity (MFI) of the 39 non-HLA antigens were compared within the groups, obtaining a statistically significant differences in protein tyrosine phosphatase receptor type N (P < .04) with a MFI mean of 1408 vs 4931 for KT and GL groups, respectively. However, no significant differences were observed in non-HLA MFI between ABMR and non-ABMR KT recipients.
CONCLUSIONS: The presence of non-HLA antibodies in HS is high. The levels of anti-protein tyrosine phosphatase receptor type N before transplant could indicate a potential risk of GL, although longitudinal studies with large number of cases are needed to define anti-non-HLA profiles of risk of ABMR.
摘要：
背景：非HLA抗体在实体器官移植和高度致敏（HS）患者中的作用受到特别关注，因为它可能参与移植物丢失（GL）和/或抗体介导的排斥（ABMR）。列出的非HLA抗体的鉴定可能会提供有关移植前免疫风险增加的更深入的信息。我们旨在鉴定HS患者移植前可能涉及GL的非HLA抗体。
方法：在MarquédeValdecilla大学医院接受移植的19例HS患者的移植前样本进行了HLA抗体和基于Luminex平台分析的一组39种非HLA抗原的研究。
结果：11名患者（57.9％）维持移植物（KT组），而8例(42.1%)的GL中位数为30天.在各组内比较39种非HLA抗原的中值荧光强度(MFI),KT和GL组的蛋白酪氨酸磷酸酶受体N型差异具有统计学意义（P<.04），MFI平均值为1408vs4931，分别。然而,ABMR和非ABMRKT受者的非HLAMFI无显著差异.
结论：非HLA抗体在HS中的存在很高。移植前的抗蛋白酪氨酸磷酸酶受体N型水平可能表明GL的潜在风险，尽管需要大量病例的纵向研究来确定ABMR的抗非HLA风险谱。
方法：在MarquédeValdecilla大学医院接受移植的19例HS患者的移植前样本进行了HLA抗体和基于Luminex平台分析的一组39种非HLA抗原的研究。
结果：11名患者（57.9％）维持移植物（KT组），而8例(42.1%)的GL中位数为30天.在各组内比较39种非HLA抗原的中值荧光强度(MFI),KT和GL组的蛋白酪氨酸磷酸酶受体N型差异具有统计学意义（P<.04），MFI平均值为1408vs4931，分别。然而,ABMR和非ABMRKT受者的非HLAMFI无显著差异.
结论：非HLA抗体在HS中的存在很高。移植前的抗蛋白酪氨酸磷酸酶受体N型水平可能表明GL的潜在风险，尽管需要大量病例的纵向研究来确定ABMR的抗非HLA风险谱。
